Cytokinetics, Inc.
Cytokinetics Reports Q4 2023 Financial Results and Key Clinical Updates
Summary
Cytokinetics, Incorporated reported its financial results for Q4 2023 and the full year, with a net loss of $136.9 million for Q4 and $526.2 million for the year. Key highlights include positive results from the SEQUOIA-HCM trial for aficamten, which demonstrated statistically significant improvements in exercise capacity. The company also announced plans to submit a New Drug Application (NDA) for aficamten to the FDA in Q3 2024 and a Marketing Authorization Application (MAA) to the EMA in Q4 2024. Cytokinetics expects to present primary results from SEQUOIA-HCM at a medical conference in Q2 2024 and provided 2024 financial guidance with an anticipated cash runway of approximately two years.
Profitelligence Alerts
Get alerts for CYTK
Be first to know when Cytokinetics, Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Cytokinetics, Inc.
Cytokinetics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel muscle activators as potential treatments for debilitating diseases. Primarily, the company's work aims to address unmet medical needs in the fields of neurology and cardiology, offering therapeutic solutions that target muscle function. Cytokinetics' research centers on small molecule drugs that modulate muscle performance, which could significantly aid patients suffering from heart failure, amyotrophic lateral sclerosis (ALS), and other muscle-related conditions. The company is actively involved in clinical trials and collaborates with other notable entities in its quest for innovative medical advancements. Its contributions to the healthcare sector exemplify the growing role of targeted therapy in improving patient outcomes. Headquartered in South San Francisco, California, Cytokinetics operates as a key player in the biotechnology landscape, with a commitment to pioneering treatments that leverage the complex mechanisms of muscle biology.
Official SEC Documents
Advertisement